CNBC's Meg Tirrell reports the latest biotech and health care news including Clovis Oncology's new ovarian cancer drug study sending shares up.
Jim Cramer has one worry that stands out among the rest when Janet Yellen makes her call at Wednesday’s Fed meeting.
Jim Cramer gives his opinions on stock plays at lightning speed, including this group of struggling tech stocks.
As the world's largest cancer research conference gets underway, here's how to play the stocks.
CNBC's Meg Tirrell reports on what to expect out of the ASCO conference and looks at Kensho data to see which companies have historically performed well in the space.
Jim Cramer rattles off his take on caller favorite stocks, including this popular tech play.
Biotechnology stocks deepened their rout Friday, as fears of drugs prices continued to mount.
After trailing this bull market for 6 years, hedge funds are starting to outperform as volatility increases and stock picking becomes more difficult.
Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.
Check out which companies are making headlines after the bell Tuesday: Apple, Pier 1, Western Union & more.
A senior Jefferies banker, Sage Kelly, is on leave after intense publicity around salacious allegations made by his wife in divorce proceedings.
A nasty Wall Street divorce has touched two biotech CEOs and appears to have moved their company stocks down over drug use allegations.
It's time for the Lightning Round. Cramer makes the call on viewer favorites.
A crush of big cap earnings and arguably the most important economic reports until September make next week the busiest of the summer for markets.
After a string of mergers, Cramer thinks investors may be looking at significantly higher valuations in parts of the market.
Jim Cramer hit the road Wednesday to investigate the prospects of 4 firms headquartered in Seattle.
Some of Wednesday's midday movers:
There are a handful of stocks out there that the market loves and should take even higher by the end of the year, CNBC's Jim Cramer said Thursday.
Cramer always notes superlatives in any stock. What does he think of this play now?